News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Merck & Co.
NEWS
JOBS
IN THE PRESS
AWARDS
NEWS
Business
Booming Moderna Eyes Six Human Trials in 2016, Inks Deals with AstraZeneca PLC, Merck & Co. and Signed Huge Lease in Cambridge for R&D Growth
January 12, 2016
·
3 min read
Deals
Merck & Co. and Quartet Medicine Ink Built-To-Buy Deal Worth Up To $575 Million
January 6, 2016
·
2 min read
BioCapital
Is Merck & Co. About To Derail Gilead?
December 31, 2015
·
1 min read
Business
New York Biotech Kallyope Launches with $44 Million and a Merck & Co. Vet at Its Helm
December 10, 2015
·
2 min read
Biotech Bay
Merck & Co. CEO: In Healthcare, We Cannot Afford To Fail
December 4, 2015
·
1 min read
Biotech Bay
Merck & Co. CEO Calls Shkreli “A Hedge Fund Guy Masquerading As A Pharma Exec”
November 23, 2015
·
1 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson’s Studies
January 21, 2026
·
5 min read
Press Releases
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
January 20, 2026
·
63 min read
Press Releases
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
January 19, 2026
·
3 min read
Press Releases
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
January 13, 2026
·
3 min read
Press Releases
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
January 13, 2026
·
6 min read
Press Releases
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
January 7, 2026
·
19 min read
Press Releases
Merck to Complete Acquisition of Cidara Therapeutics
January 7, 2026
·
6 min read
Press Releases
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
January 7, 2026
·
3 min read
Press Releases
Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
·
3 min read
Press Releases
BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer
January 5, 2026
·
7 min read
